ATE474568T1 - Synergistische kombination von (-) -gossypol mit docetaxel oder paclitaxel zur behandlung von krebs. - Google Patents

Synergistische kombination von (-) -gossypol mit docetaxel oder paclitaxel zur behandlung von krebs.

Info

Publication number
ATE474568T1
ATE474568T1 AT02734614T AT02734614T ATE474568T1 AT E474568 T1 ATE474568 T1 AT E474568T1 AT 02734614 T AT02734614 T AT 02734614T AT 02734614 T AT02734614 T AT 02734614T AT E474568 T1 ATE474568 T1 AT E474568T1
Authority
AT
Austria
Prior art keywords
bcl
gossypol
cancer
docetaxel
paclitaxel
Prior art date
Application number
AT02734614T
Other languages
English (en)
Inventor
Shaomeng Wang
Dajun Yang
Original Assignee
Univ Michigan
Univ Georgetown
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Michigan, Univ Georgetown filed Critical Univ Michigan
Application granted granted Critical
Publication of ATE474568T1 publication Critical patent/ATE474568T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Epoxy Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT02734614T 2001-05-30 2002-05-30 Synergistische kombination von (-) -gossypol mit docetaxel oder paclitaxel zur behandlung von krebs. ATE474568T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29398301P 2001-05-30 2001-05-30
PCT/US2002/017206 WO2002097053A2 (en) 2001-05-30 2002-05-30 Small molecule antagonists of bcl2 family proteins

Publications (1)

Publication Number Publication Date
ATE474568T1 true ATE474568T1 (de) 2010-08-15

Family

ID=31495521

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02734614T ATE474568T1 (de) 2001-05-30 2002-05-30 Synergistische kombination von (-) -gossypol mit docetaxel oder paclitaxel zur behandlung von krebs.

Country Status (18)

Country Link
US (1) US20030008924A1 (de)
EP (1) EP1474121B1 (de)
JP (1) JP2005515158A (de)
KR (1) KR20040108528A (de)
CN (1) CN1589135A (de)
AT (1) ATE474568T1 (de)
AU (1) AU2002305769B2 (de)
CA (1) CA2449245A1 (de)
DE (1) DE60237115D1 (de)
ES (1) ES2349349T3 (de)
HK (1) HK1071066A1 (de)
IL (1) IL159110A0 (de)
MX (1) MXPA03010977A (de)
NO (1) NO20035301D0 (de)
NZ (1) NZ529792A (de)
SG (1) SG157952A1 (de)
WO (1) WO2002097053A2 (de)
ZA (1) ZA200309306B (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO20023357D0 (no) * 2002-04-19 2002-07-11 Amersham Health As Blanding
US20070060615A1 (en) * 2003-02-18 2007-03-15 University Of South Florida Method of Modulating Apoptosis Through Modulation of E2F1
DE602004028880D1 (de) * 2003-06-25 2010-10-07 Burnham Inst La Jolla Analoga von Apogossypol zur Verwendung in der Behandlung von Krebs
CA2561303C (en) * 2004-03-25 2011-01-18 The Regents Of The University Of Michigan Gossypol co-crystals and the use thereof
CN101006065B (zh) 2004-06-17 2012-07-11 英菲尼蒂发现公司 抑制bcl蛋白与结合伴侣的相互作用的化合物和方法
US7842815B2 (en) * 2004-06-17 2010-11-30 Infinity Pharmaceuticals, Inc. Compounds and methods for inhibiting the interaction of BCL proteins with binding partners
US20060144723A1 (en) * 2004-11-02 2006-07-06 Mary Fuller Device for securing valuables
CA2600797A1 (en) * 2005-03-11 2006-09-21 The Regents Of The University Of Michigan Chromen-4-one inhibitors of anti-apoptotic bcl-2 family members and the uses thereof
TWI403320B (zh) 2005-12-16 2013-08-01 Infinity Discovery Inc 用於抑制ｂｃｌ蛋白和結合夥伴間之交互作用的化合物及方法
WO2007126840A2 (en) * 2006-03-30 2007-11-08 The Regents Of The University Of Michigan Production of gossypol co-crystals
WO2007145704A2 (en) 2006-04-24 2007-12-21 Gloucester Pharmaceuticals Gemcitabine combination therapy
WO2007146730A2 (en) 2006-06-08 2007-12-21 Gloucester Pharmaceuticals Deacetylase inhibitor therapy
TWI389895B (zh) 2006-08-21 2013-03-21 Infinity Discovery Inc 抑制ｂｃｌ蛋白質與結合夥伴間之交互作用的化合物及方法
US7857804B2 (en) 2006-09-01 2010-12-28 Mccaffrey Timothy A Use of Bcl inhibitors for the prevention of fibroproliferative reclosure of dilated blood vessels and other iatrogenic fibroproliferative disorders
US20090030088A1 (en) * 2007-04-20 2009-01-29 Clemson University Therapeutic benefits of gossypol, 6-methoxy gossypol, and 6,6'-dimothxy gossypol
WO2009036035A1 (en) * 2007-09-10 2009-03-19 Curis, Inc. Bcl-2 inhibitors
WO2009052443A1 (en) * 2007-10-19 2009-04-23 Burnham Institute For Medical Research Naphthalene-based inhibitors of anti-apoptotic proteins
CA2733930A1 (en) * 2008-08-14 2010-02-18 The Uab Research Foundation Anti-arrhythmia agents, methods of their use, methods of their identification, and kits therefore
MX2011006167A (es) * 2008-12-11 2011-07-28 Abraxis Bioscience Llc Combinaciones y modos de administracion de agentes terapeuticos y terapia de combinacion.
MX2012004064A (es) * 2009-10-08 2012-06-08 Sanford Burnham Med Res Inst Derivados apogosipolona como agentes antineoplasicos.
MY185130A (en) 2010-07-12 2021-04-30 Celgene Corp Romidepsin solid forms and uses thereof
US8859502B2 (en) 2010-09-13 2014-10-14 Celgene Corporation Therapy for MLL-rearranged leukemia
WO2012151544A1 (en) * 2011-05-05 2012-11-08 Wisconsin Alumni Research Foundation Micelles for the solubilization of gossypol
US8940737B2 (en) * 2011-10-14 2015-01-27 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
AU2012355624A1 (en) 2011-12-23 2014-07-17 Novartis Ag Compounds for inhibiting the interaction of BCL2 with binding partners
CN104136429A (zh) 2011-12-23 2014-11-05 诺华股份有限公司 用于抑制bcl2与结合配偶体相互作用的化合物
CN104125954A (zh) 2011-12-23 2014-10-29 诺华股份有限公司 用于抑制bcl2与结合配偶体相互作用的化合物
MX2014007725A (es) 2011-12-23 2015-01-12 Novartis Ag Compuestos para inhibir la interaccion de bcl2 con los componentes de enlace.
CA2859862A1 (en) 2011-12-23 2013-06-27 Novartis Ag Compounds for inhibiting the interaction of bcl2 with binding partners
AU2013202506B2 (en) 2012-09-07 2015-06-18 Celgene Corporation Resistance biomarkers for hdac inhibitors
AU2013202507B9 (en) 2012-11-14 2015-08-13 Celgene Corporation Inhibition of drug resistant cancer cells
NZ630311A (en) 2013-12-27 2016-03-31 Celgene Corp Romidepsin formulations and uses thereof
WO2015123618A1 (en) * 2014-02-14 2015-08-20 Arizona Board Of Regents For The University Of Arizona Method for increasing bcl2 gene expression
EP3139942B1 (de) 2014-05-05 2019-12-18 Bioventures, Llc Zusammensetzungen und verfahren zur hemmung antiapoptotischer bcl-2-proteine als anti-aging-mittel
WO2016014625A1 (en) 2014-07-22 2016-01-28 Board Of Trustees Of The University Of Arkansas Compositions and methods for selectively depleting senescent cells
CN105884634B (zh) * 2015-01-05 2019-06-04 南开大学 棉酚衍生物和它们的制备,在农药上的应用及抗癌活性
US10975051B2 (en) 2015-08-12 2021-04-13 Memorial Sloan Kettering Cancer Center Phenylsulfonamido-benzofuran derivatives and uses thereof in the treatment of proliferative diseases
WO2017087810A1 (en) * 2015-11-20 2017-05-26 Memorial Sloan-Kettering Cancer Center Method for screening inhibitors targeting anti-apoptotic survival pathways
WO2017142348A1 (ko) * 2016-02-18 2017-08-24 연세대학교 산학협력단 폴리페놀 화합물을 유효성분으로 포함하는 암 치료용 약학조성물
EP3417853A4 (de) 2016-02-18 2019-10-30 Industry-Academic Cooperation Foundation Yonsei University Pharmazeutische zusammensetzung zur behandlung von krebs mit einer polyphenolverbindung als wirkstoff
CA3018991A1 (en) 2016-04-21 2017-10-26 Bioventures, Llc Compounds that induce degradation of anti-apoptotic bcl-2 family proteins and the uses thereof
CN109718377B (zh) * 2017-10-31 2021-03-26 中国科学院脑科学与智能技术卓越创新中心 KPNB1抑制剂和Bcl-xL抑制剂在制备抗肿瘤药物中的应用
WO2019144117A1 (en) 2018-01-22 2019-07-25 Bioventures, Llc Bcl-2 proteins degraders for cancer treatment
CN109876145A (zh) * 2019-04-25 2019-06-14 中国科学院化学研究所 醋酸棉酚和化疗药的联合用药物
CA3142361A1 (en) 2019-06-12 2020-12-17 Juno Therapeutics, Inc. Combination therapy of a cell-mediated cytotoxic therapy and an inhibitor of a prosurvival bcl2 family protein
WO2022133030A1 (en) 2020-12-16 2022-06-23 Juno Therapeutics, Inc. Combination therapy of a cell therapy and a bcl2 inhibitor
WO2023107606A1 (en) 2021-12-09 2023-06-15 University Of Florida Research Foundation, Incorporated Bcl-xl/bcl-2 dual degraders for treatment of cancers
WO2023220655A1 (en) 2022-05-11 2023-11-16 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4806568A (en) * 1985-09-12 1989-02-21 Research Corporation Gossypol derivatives
US5026726A (en) * 1989-12-11 1991-06-25 The University Of New Mexico Gossylic iminolactones and gossylic lactones and their anti-viral activities
US5385936A (en) * 1990-07-12 1995-01-31 The United States Of America As Represented By The Secretary Of The Department Of The Health And Human Services Gossypol acetic acid for the treatment of cancer
US9002545B2 (en) 2011-01-07 2015-04-07 Wabtec Holding Corp. Data improvement system and method

Also Published As

Publication number Publication date
NZ529792A (en) 2007-04-27
HK1071066A1 (en) 2005-07-08
ZA200309306B (de) 2006-07-26
SG157952A1 (en) 2010-01-29
EP1474121A4 (de) 2006-05-03
MXPA03010977A (es) 2005-04-08
EP1474121B1 (de) 2010-07-21
DE60237115D1 (de) 2010-09-02
CA2449245A1 (en) 2002-12-05
ES2349349T3 (es) 2010-12-30
CN1589135A (zh) 2005-03-02
IL159110A0 (en) 2004-06-01
KR20040108528A (ko) 2004-12-24
WO2002097053A3 (en) 2004-09-10
WO2002097053A2 (en) 2002-12-05
JP2005515158A (ja) 2005-05-26
US20030008924A1 (en) 2003-01-09
AU2002305769B2 (en) 2007-07-19
EP1474121A2 (de) 2004-11-10
NO20035301D0 (no) 2003-11-28

Similar Documents

Publication Publication Date Title
ATE474568T1 (de) Synergistische kombination von (-) -gossypol mit docetaxel oder paclitaxel zur behandlung von krebs.
BR112012006252A2 (pt) "formas cristalinas de abt-263 e solvatos para o uso no tratamento de doenças relacionadas á proteína bcl-2".
BRPI0606891A2 (pt) anticorpos dr5 e usos dos mesmos
DE60201824D1 (de) Nahrungsergänzung zur behandlung von makula degeneration
DE60031268D1 (de) Verfahren und zusammansetzung zur behandlung von krebs
EA200700175A1 (ru) Композиции и способы лечения воспалительных заболеваний
ATE526991T1 (de) Zusammensetzungen und ihre verwendungen für die gentherapeutische behandlung von knochenerkrankungen
ATE361084T1 (de) Topische pharmazeutische zusammensetzungen mit proanthocyanidinen, glycyrrhetinic säure und telmesteine zur behandlung von dermatitis
NO20060978L (no) Farmasoytiske blandingr for behandling av prematur ejakulasjon ved pulmonal inhalering
MX2009000285A (es) Piperidinas sustituidas que incrementan la actividad de p53 y usos de las mismas.
ATE495739T1 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
DE60330161D1 (de) Rifalazil zur behandlung von infektionen mit clostridium difficile
NO20085147L (no) Sammensetning for behandling av motstandsdyktige kreftformer omfattende oridonin
NO20082862L (no) Nye alkylfosfolipidderivater med redusert cytotoksisitet og anvendelse derav
ATE406884T1 (de) Zusammensetzungen mit pantothensäure oder derivaten davon und ihre verwendung zur stimulierung des appetits
ATE414526T1 (de) Zubereitungen zur behandlung von arthritischen erscheinungen
DE60313434D1 (de) Verfahren und zusammensetzungen zur behandlung von hyperproliferativen zuständen
GT200200279A (es) Anticuerpo que inhibe la actividad del factor de las celulas precursoras y su uso para el tratamiento del asma
ATE541855T1 (de) Weitere kristalline formen von rostafuroxin
DE602005015329D1 (de) Rutheniumkomplexe zur krebsbehandlung
DE602004005821D1 (de) Enteralpräparat zur vorbeugung gegen bzw. behandlung von sepsis
BRPI0410967A (pt) compostos, composições e seus usos para o tratamento de infecções por vìrus da famìlia flaviviridae
EA200700413A1 (ru) Ариламинкетоны, способ их получения, фармацевтические композиции, содержащие их, и их применение
BRPI0411168A (pt) composição para o tratamento dos cabelos, usos de uma composição e método de tratamento dos cabelos
ATE460168T1 (de) Nicht-radioaktives strontiummittel zur behandlung von krebs

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties